Skip to main content

Pressmeddelanden Visa alla 161 träffar

AstraZeneca redefines cancer treatment  with practice-changing data at ESMO 2019

AstraZeneca redefines cancer treatment with practice-changing data at ESMO 2019

Pressmeddelanden   •   Sep 16, 2019 08:13 CEST

AstraZeneca will unveil a series of breakthrough data across multiple cancer types in its mission to one day eliminate cancer as a cause of death at the European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain, 27 September to 1 October 2019. ​

Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer

Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer

Pressmeddelanden   •   Sep 04, 2019 08:22 CEST

AstraZeneca today announced that it has received marketing authorisation from China’s National Medical Products Administration for Tagrisso (osimertinib) as a 1st-line treatment for adults with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have the genetic mutations of epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitutions.

Update on the Phase III NEPTUNE trial of Imfinzi plus  tremelimumab in Stage IV non-small cell lung cancer

Update on the Phase III NEPTUNE trial of Imfinzi plus tremelimumab in Stage IV non-small cell lung cancer

Pressmeddelanden   •   Aug 21, 2019 08:03 CEST

​AstraZeneca today announced final overall survival (OS) results from the Phase III NEPTUNE trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) in combination with tremelimumab, an anti-CTLA4 antibody, vs. standard-of-care (SoC) platinum-based chemotherapy in previously-untreated Stage IV (metastatic) non-small cell lung cancer (NSCLC) patients.

Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer

Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer

Pressmeddelanden   •   Aug 14, 2019 08:09 CEST

AstraZeneca and MSD Inc., Kenilworth, N.J., US today announced positive results from the Phase III PAOLA-1 trial in women with advanced ovarian cancer. The trial, in the 1st-line maintenance setting, compared Lynparza (olaparib) added to standard-of-care (SoC) bevacizumab vs. bevacizumab alone in women with or without BRCA gene mutations.

Bilder Visa alla 14 träffar

Imfinzi SE-FI-Carton+Vial-120mg+500mg.  Bild får endast användas av medicinsk media.

Imfinzi SE-FI-Carton+Vial...

For the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC) for the treatment of locally-advanced, unresectabl...

Licens Creative Commons erkännande
Ladda ner
Storlek

2,16 MB • 3078 x 2476 px

Tagrisso, osimertinib 40 mg

Tagrisso, osimertinib 40 mg

TAGRISSO (OSIMERTINIB), BEHANDLING FÖR PATIENTER MED EGFR T790M MUTATIONSPOSITIV METASTASERAD ICKE-SMÅCELLIG LUNGCANCER.

Licens Creative Commons erkännande
Ladda ner
Storlek

83,9 KB • 600 x 488 px

Tagrisso, osimertinib 80 mg

Tagrisso, osimertinib 80 mg

TAGRISSO (OSIMERTINIB), BEHANDLING FÖR PATIENTER MED EGFR T790M MUTATIONSPOSITIV METASTASERAD ICKE-SMÅCELLIG LUNGCANCER.

Licens Creative Commons erkännande
Ladda ner
Storlek

85,8 KB • 600 x 488 px

Circulating tumour DNA

Circulating tumour DNA

Minute pieces of tumour DNA circulating in the bloodstream

Licens Creative Commons erkännande
Ladda ner
Storlek

16,8 MB • 7205 x 4053 px

Dokument Visa alla 14 träffar